HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Crum, C. P. Articles by Lee, Y. Search for Related Content PubMed PubMed Citation Articles by Crum, C. P. Articles by Lee, Y.

Lessons from BRCA: The Tubal Fimbria Emerges as an Origin for Pelvic Serous Cancer

Christopher P. Crum, MD, Division of Women’s and Perinatal Pathology, Department of Pathology, Brigham and Women’s Hospital, Boston, MA 02115
Ronny Drapkin, MD, PhD, Division of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115
David Kindelberger, MD, Division of Women’s and Perinatal Pathology, Department of Pathology, Brigham and Women’s Hospital, Boston, MA 02115
Fabiola Medeiros, MD, Division of Women’s and Perinatal Pathology, Department of Pathology, Brigham and Women’s Hospital, Boston, MA 02115
Alexander Miron, PhD, Division of Cancer Biology, Dana Farber Cancer Institute, Boston, MA 02115
Yonghee Lee, MD, Division of Women’s and Perinatal Pathology, Department of Pathology, Brigham and Women’s Hospital, Boston, MA 02115

Reprint Requests: Christopher P. Crum, MD, Department of Pathology, Brigham and Women’s Hospital, 75 Francis Street, Boston, MA 02115, Tel: 617-732-5481, Fax: 617-264-5125, Email: ccrum{at}partners.org

Ovarian epithelial cancer is diagnosed in approximately 25,000 women yearly in the United States, accounting for approximately 12,500 deaths. Of these tumors, serous cancer is the most lethal, due to its capacity to spread beyond the reproductive tract and involve the peritoneal surfaces or distant organs. Conventional classification systems designate tumor origins principally on the location of the largest tumor. However, despite the fact that the largest tumors typically involve the ovaries, demonstrations of a precise starting point for these tumors, including precursor lesions, have been inconsistent. In recent years, a major effort to prevent serous cancer in genetically susceptible women with mutations in BRCA1 or BRCA2 has spawned the practice of prophylactic salpingo-oophorectomy. This practice has surprisingly revealed that many early cancers in these women arise in the fallopian tube, and further studies have pinpointed the distal (fimbrial) portion as the most common site of origin. Emerging studies that carefully examine the fallopian tubes suggest a high frequency of early cancer in the fimbria in unselected women with ovarian and peritoneal serous carcinoma, raising the distinct possibility that a significant proportion of these tumors have a fimbrial origin. The evidence for these discoveries and their relevance to serous cancer classification, early detection and prevention are addressed in this review. A model for pelvic serous cancer is proposed that takes into account five distinct variables which ultimately impact on origin and tumor distribution: (1) location of target epithelium, (2) genotoxic stress, (3) type of epithelium, (4) mitigating genetic factors, and (5) tumor spread pattern. Ultimately, this model illustrates the importance of identifying cancer precursors, inasmuch as these entities are useful as both surrogate endpoints for their respective malignancies in epidemiologic studies and natural targets for cancer prevention.

Key Words: BRCA, Fallopian tube neoplasms • Fimbria • Ovarian neoplasms • p53 • SEE-FIM • Serous carcinoma

This article has been cited by other articles:

				J. L. Hecht, J. Kotsopoulos, S. E. Hankinson, and S. S. Tworoger Relationship between Epidemiologic Risk Factors and Hormone Receptor Expression in Ovarian Cancer: Results from the Nurses' Health Study Cancer Epidemiol. Biomarkers Prev., May 1, 2009; 18(5): 1624 - 1630. [Abstract] [Full Text] [PDF]

				J. S Fleming, H J. McQuillan, M. J Millier, and G. C Sellar Expression of ovarian tumour suppressor OPCML in the female CD-1 mouse reproductive tract Reproduction, April 1, 2009; 137(4): 721 - 726. [Abstract] [Full Text] [PDF]

				R. Sasaki, M. Narisawa-Saito, T. Yugawa, M. Fujita, H. Tashiro, H. Katabuchi, and T. Kiyono Oncogenic transformation of human ovarian surface epithelial cells with defined cellular oncogenes Carcinogenesis, March 1, 2009; 30(3): 423 - 431. [Abstract] [Full Text] [PDF]

				K. Levanon, C. Crum, and R. Drapkin New Insights Into the Pathogenesis of Serous Ovarian Cancer and Its Clinical Impact J. Clin. Oncol., November 10, 2008; 26(32): 5284 - 5293. [Abstract] [Full Text] [PDF]

				A. A. Tone, H. Begley, M. Sharma, J. Murphy, B. Rosen, T. J. Brown, and P. A. Shaw Gene Expression Profiles of Luteal Phase Fallopian Tube Epithelium from BRCA Mutation Carriers Resemble High-Grade Serous Carcinoma Clin. Cancer Res., July 1, 2008; 14(13): 4067 - 4078. [Abstract] [Full Text] [PDF]

				N. Scholler, K. A. Lowe, L. A. Bergan, A. V. Kampani, V. Ng, R. M. Forrest, J. D. Thorpe, J. A. Gross, B. M. Garvik, R. Drapkin, et al. Use of Yeast-Secreted In vivo Biotinylated Recombinant Antibodies (Biobodies) in Bead-Based ELISA Clin. Cancer Res., May 1, 2008; 14(9): 2647 - 2655. [Abstract] [Full Text] [PDF]